CD47 and neoplasm: Collectively, these data demonstrate that simultaneous targeting of PD-L1 and CD47 elicits robust antitumor responses, characterized by inhibition of tumor growth, enhanced apoptosis, and impaired angiogenesis, while monotherapies achieved only limited efficacy.